Fusion proteins
AssigneesAllergan, Inc., Ipsen Bioinnovation Limited
InventorsKeith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
Life of this patent
Estimating the term…
Loading patent…
AssigneesAllergan, Inc., Ipsen Bioinnovation Limited
InventorsKeith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
Estimating the term…
A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.
A method of treating or ameliorating pain in a subject, comprising administering to said subject a therapeutically effective amount of a polypeptide fusion protein comprising:
Dependencies are inferred from the claim text.